Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;80(4):404-411.
doi: 10.1111/anae.16532. Epub 2025 Jan 7.

Prevalence and outcomes of patients taking oral corticosteroids for over 1 month undergoing major surgery in England 2010-2020

Affiliations

Prevalence and outcomes of patients taking oral corticosteroids for over 1 month undergoing major surgery in England 2010-2020

Jessica Harris et al. Anaesthesia. 2025 Apr.

Abstract

Introduction: Approximately 1% of the UK population is prescribed oral corticosteroids at any one time. It is not known how many of these patients present for major surgery. We aimed to establish the prevalence, characteristics and outcomes of patients taking oral corticosteroids.

Methods: We identified patients aged > 18 y undergoing major surgery between 1 April 2010 and 31 March 2020 from Hospital Episode Statistics with linked Clinical Practice Research Datalink data and the Office for National Statistics Mortality register in England. Prescribing data were used to define three sets of patients: 'low-dose' - taking ≤ 7.5 mg oral prednisolone equivalents per day for at least 28/91 days before surgery; 'high-dose' - taking > 7.5 mg oral prednisolone equivalents per day for at least 28/ 91 days before surgery; and a 'no-steroids' group. We used ≤ 7.5 mg of prednisolone equivalents per day as our threshold, as this would likely exclude almost all patients who were taking corticosteroids as replacement for absolute adrenal/pituitary deficiency.

Results: We identified 1,999,326 adult patients for inclusion in the dataset: 1,929,291 (96.5%) in the no-steroids; 63,353 (3.2%) in the low-dose group; and 6682 (0.3%) in the high-dose group. Median (IQR [range]) duration of hospital stay increased with increasing dose of corticosteroid (no-steroid 3 (0-14 [0-14,739]); low-dose 5 (1-26 [1-8079]); and high-dose 7 (2-28 [0-6956]) days). Mortality after the index surgery was 1.5%, 3.8% and 8.9% at 30 days and 5.5%, 11.6% and 39.9% at 1 year for no-steroids, low-dose and high-dose groups, respectively.

Conclusion: Around 1 in 29 patients undergoing major surgery are taking oral corticosteroids for > 28 days in the 3 months before major surgery. Their outcomes are poor and warrant highlighting within care pathways to aid risk prediction and mitigation.

Keywords: adrenal gland; corticosteroids; glucocorticoids; routinely collected data; surgery.

PubMed Disclaimer

Similar articles

References

    1. Woodcock T, Barker P, Daniel S, et al. Guidelines for the management of glucocorticoids during the peri‐operative period for patients with adrenal insufficiency: guidelines from the Association of Anaesthetists, the Royal College of Physicians and the Society for Endocrinology UK. Anaesthesia 2020; 75: 654–663. 10.1111/anae.1496. - DOI - PubMed
    1. Liu MM, Reidy AB, Saatee S, Collard CD. Perioperative steroid management: approaches based on current evidence. Anesthesiology 2017; 127: 166–172. 10.1097/ALN.0000000000001659. - DOI - PubMed
    1. Marik PE, Varon J. Requirement of perioperative stress doses of corticosteroids: a systematic review of the literature. Arch Surg 2008; 143: 1222–1226. 10.1001/archsurg.143.12.1222. - DOI - PubMed
    1. Seo KH. Perioperative glucocorticoid management based on current evidence. Anesth Pain Med (Seoul) 2021; 16: 8–15. 10.17085/apm.20089. - DOI - PMC - PubMed
    1. Barker OJH, Ramesh AV, Kangesan I, et al. The Peri‐operative Replacement of Exogenous Steroids (PREdS): national audit of current peri‐operative prescribing for patients taking therapeutic steroids. Anaesthesia 2024; 79: 1042–1052. 10.1111/anae.16388. - DOI - PubMed

Substances